Clinical trialNCT07110246RecruitingPhase 2Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

SponsorUniversity of California, San FranciscoEnrollment96BRAF V600 MutationLow Grade Glioma of BrainLow-grade GliomaRecurrent Low Grade Glioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Sabine Mueller, MD, PHD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Girish Dhall, MD
Recruiting
University of California, San Francisco
San Francisco, California, United States
Sabine Mueller, MD, PhD, MAS
Recruiting
Children'S National Hospital
Washington D.C., District of Columbia, United States
Lindsay Kilburn, MD
Recruiting
University of Florida
Gainesville, Florida, United States
Elias Sayour, MD, PhD
Recruiting
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Alicia Lenzen, MD
Recruiting
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, United States
Brian Weiss, MD
Recruiting
John Hopkins Medical Center
Baltimore, Maryland, United States
Kenneth Cohen, MD, MBA
Recruiting
St. Louis Children'S Hospital Washington University in St. Louis
St Louis, Missouri, United States
Mohamed S Abdelbaki, MD
Recruiting
Joseph M. Sanzari Children'S Hospital at Hackensack University Medical Center
Hackensack, New Jersey, United States
Derek Hanson, MD
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Daniel Landi, MD
Recruiting
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Amar Gajjar, MD
Recruiting
University of Utah
Salt Lake City, Utah, United States
Nicholas Whipple, MD, MPH
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dabrafenib →Trametinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Nov 2025
Primary completion: 31 Mar 2032
Completion: 31 Mar 2032
Last update posted: 26 Oct 2026
Registered enrollment: 96
Registry id: NCT07110246

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.